Skip to main content

Table 1 CONRAD 135 study design

From: Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies

Product Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Intravaginal ring (IVR) (n = 20) Screening Insert IVR1
(24–36 h)
Remove IVR1
Vaginal swab
Insert IVR2 (7–10 days)
Remove IVR2
Vaginal swab
Insert IVR3 (28–32 days)
Remove IVR3
Vaginal swab
Gel, film, or insert (n = 10 each) Screening Baseline swab
Apply product in clinic
Swab 15 min post-product
Swabs at home each day, Day 1–Day 7
Baseline swab
Apply product in clinic
Swabs 15 min post-product
Unprotected intercourse 8–16 h post-product use
Swabs at home each day, Day 1–Day 7
Final swab N/A